Red blood cells membrane vehicle co-delivering DOX and IR780 for effective prostate cancer therapy
- PDF / 717,441 Bytes
- 8 Pages / 584.957 x 782.986 pts Page_size
- 36 Downloads / 162 Views
Red blood cells membrane vehicle co-delivering DOX and IR780 for effective prostate cancer therapy Datian Zhang1, Chengfu Zhou2, Feng Liu3, Tao Ding3, Zhong Wang3,a) 1
Department of Urology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121001, P.R. China The First People’s Hospital of Tai’an (affiliated to Shandong First Medical University), Tai’an, Shandong 271016, P.R. China 3 Department of Urology, Sixth People’s Hospital South Campus Affiliated to Shanghai Jiaotong University, Shanghai 201499, P.R. China a) Address all correspondence to this author. e-mail: [email protected] 2
Received: 12 May 2020; accepted: 21 August 2020
The cellular accumulation of drug delivery systems (DDSs) is a critical parameter to determine the final outcome of cancer chemotherapy. Herein, we designed a red blood cells membrane-based vehicle (RV) and employed it to load both doxorubicin (Dox) and IR 780 (RV/I-D). The photothermal-assisted chemotherapy efficacy of RV/I-D on the treatment of cancer was tested on a prostate cancer model. Excitingly, the results showed that RV/I-D was stable and safe nanoparticles with size at about 100 nm. Moreover, upon the increase of system temperature using photothermal effects of IR780, the drug release of the DDS was accelerated. Above all, the DDS also increased the accumulation of drugs into the Dox-resistant prostate cancer cells (PC-3/Dox) both in vitro and in vivo and showed enhanced anticancer performance.
Introduction With the advancing of cancer treatments, more and more researches have realized that the cellular accumulation of drug delivery systems (DDSs) is a critical parameter to determine the final outcome of cancer chemotherapy. There are some well-recognized reasons responsible for this dilemma, among which unsatisfied cell internalization of the DDS as well as drug resistance of cancer cells are recognized as two important obstacles [1, 2]. Previous studies have shown the poor performance of free drugs on cancer therapy are mainly due to the quick excretion of internalized drug molecules. Although DDS at the nanoscale can overcome this adverse effect in part, the final performance is greatly impaired due to the drug resistance nature of cells [3, 4]. Therefore, the careful design of DDS to surpass this dilemma is a great difficulty [5, 6]. The emerging of cell membrane-derived carrier is getting more and more attention due to the irreplaceable merits of this platform, including high feasibility, reproducibility, and biocompatibility [7, 8, 9]. Among the various adopted cell membrane-derived carriers, red blood cells (RBC)-derived ones are of significant importance [10, 11, 12]. It has reported that the RBC-derived carriers can afford the loading of various drugs with decent loading efficacy [13]. Moreover, the RBC with its endogenic nature can realize long circulation of encapsulated drugs for increased drug retention in tumor tissue. As a
result, the RBC-based DDSs have been widely developed and employed to load different drugs. Promising
Data Loading...
